← Back to Search

The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients

Phase 2
Waitlist Available
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month, 3 months, 6 months, 12 months and 18 months post-operation.
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial tests whether applying a small amount of mitomycin C to the eye can reduce cloudiness and scarring in patients with early-stage corneal disorders who have had corneal crosslinking. The goal is to improve their vision quality by reducing inflammation and scarring. Mitomycin C has been widely used in various eye procedures to minimize scarring and improve outcomes, demonstrating effectiveness in reducing haze and scarring in several studies.

Eligible Conditions
  • Keratoconus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 3 months, 6 months, 12 months and 18 months post-operation.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month, 3 months, 6 months, 12 months and 18 months post-operation. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Corneal haze/scarring
Secondary study objectives
Clinical haze grade
Glare
Higher-order aberrations

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: CXL with MMCActive Control1 Intervention
Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
Group II: CXL without MMCPlacebo Group1 Intervention
Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).

Find a Location

Who is running the clinical trial?

Ciusss de L'Est de l'Île de MontréalLead Sponsor
78 Previous Clinical Trials
6,411 Total Patients Enrolled
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top